<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328675</url>
  </required_header>
  <id_info>
    <org_study_id>FDongsheng-81873784</org_study_id>
    <nct_id>NCT04328675</nct_id>
  </id_info>
  <brief_title>Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China</brief_title>
  <acronym>ChALSR</acronym>
  <official_title>Registration Study of Natural History and Clinical Characteristics of Amyotrophic Lateral Sclerosis (ALS) in Mainland China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center registration study of natural history and clinical characteristics of ALS in
      mainland China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease of
      unknown etiology that is currently incurable. This study is a national multi-center
      registration study. The study collects general information of ALS patients including medical
      history, disease characteristics, clinical treatment data, and patient information for
      different visits in different centers. The aim of the study is: a) describe the distribution
      of ALS in mainland China(explore the differences in the number of ALS at different times,
      different regions, and different populations) and further find the reasons that affect the
      distribution of ALS, b) study the development of ALS in mainland China and the corresponding
      changes in the characteristics of the disease, c) explore factors that influence the
      prognosis of ALS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Effective Survival</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The length of time from the date of diagnosis to patient death or tracheotomy or ventilator-assisted breathing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The length of time from the date of diagnosis to patient death due to any cause or the last confirmed survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease progression</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The slope of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) score from the diagnosis time to the follow-up time. ALSFRS-R values from 0 to 48 and it implies better outcome when it is higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Weight decline</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The slope of decline of weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of BMI decline</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The slope of decline of BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Forced Vital Capacity (FVC)</measure>
    <time_frame>through study completion, an average of 3 month</time_frame>
    <description>The slope of decline of Forced Vital Capacity (FVC) to assess the respiratory function.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4752</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the criteria will be enrolled from multi-centers in mainland China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of laboratory-supported probable, probable, or definite ALS
             according to EI Escorial diagnostic criteria

          -  Age: 18-70 years

        Exclusion Criteria:

          -  Refuse to cooperate or reject the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsheng Fan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongsheng Fan, MD, PhD</last_name>
    <phone>+86-15611908107</phone>
    <email>dsfan@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
      <phone>+861082265032</phone>
      <email>dsfan@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

